Cellectar Biosciences, Inc. financial data

Symbol
CLRB on Nasdaq
Location
Florham Park, NJ
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 04 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 256% % 45%
Debt-to-equity 74% % -46%
Return On Equity -282% % 14%
Return On Assets -147% % -11%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4,240,129 shares -91%
Common Stock, Shares, Outstanding 4,240,129 shares 176%
Entity Public Float $12,846,737 USD -86%
Common Stock, Value, Issued $42 USD 180%
Weighted Average Number of Shares Outstanding, Basic 2,608,317 shares 114%
Weighted Average Number of Shares Outstanding, Diluted 2,608,317 shares 111%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $11,498,761 USD -56%
General and Administrative Expense $11,481,083 USD -55%
Costs and Expenses $22,979,844 USD -56%
Operating Income (Loss) $22,979,844 USD 56%
Nonoperating Income (Expense) $1,188,807 USD -84%
Net Income (Loss) Attributable to Parent $21,791,037 USD 51%
Earnings Per Share, Basic -8.35 USD/shares 77%
Earnings Per Share, Diluted -8.35 USD/shares 80%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $13,196,033 USD -43%
Assets, Current $14,038,465 USD -42%
Property, Plant and Equipment, Net $549,405 USD -27%
Operating Lease, Right-of-Use Asset $360,671 USD -17%
Other Assets, Noncurrent $29,780 USD 0%
Assets $14,978,321 USD -41%
Accounts Payable, Current $1,441,000 USD -65%
Liabilities, Current $4,749,737 USD -49%
Operating Lease, Liability, Noncurrent $309,397 USD -24%
Liabilities $5,059,134 USD -48%
Retained Earnings (Accumulated Deficit) $269,133,500 USD -8.8%
Stockholders' Equity Attributable to Parent $8,537,164 USD -40%
Liabilities and Equity $14,978,321 USD -41%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $9,383,434 USD 30%
Net Cash Provided by (Used in) Financing Activities $43,849,467 USD
Net Cash Provided by (Used in) Investing Activities $21,633 USD
Common Stock, Shares Authorized 170,000,000 shares 0%
Common Stock, Shares, Issued 4,240,129 shares 176%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $9,383,434 USD -131%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $13,196,033 USD -43%
Deferred Tax Assets, Valuation Allowance $114,339,000 USD 6.4%
Deferred Tax Assets, Gross $114,437,000 USD 6.3%
Operating Lease, Liability $410,000 USD -17%
Payments to Acquire Property, Plant, and Equipment $21,633 USD
Lessee, Operating Lease, Liability, to be Paid $511,000 USD -22%
Operating Lease, Liability, Current $100,189 USD 19%
Lessee, Operating Lease, Liability, to be Paid, Year Two $153,000 USD 2%
Lessee, Operating Lease, Liability, to be Paid, Year One $150,000 USD 2.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $101,000 USD -38%
Lessee, Operating Lease, Liability, to be Paid, Year Three $155,000 USD 1.3%
Preferred Stock, Shares Issued 36 shares
Preferred Stock, Shares Authorized 1,225 shares
Lessee, Operating Lease, Liability, to be Paid, Year Four $53,000 USD -66%
Additional Paid in Capital $277,149,844 USD 6.1%
Preferred Stock, Shares Outstanding 36 shares
Depreciation, Depletion and Amortization $56,295 USD -36%
Deferred Tax Assets, Net of Valuation Allowance $114,339,000 USD 6.4%